SEC Form 4 · accession 0001140361-16-064404
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Eric Davis
Officer — EVP, General Counsel
Period of report
Apr 29, 2016
Accepted (ET)
May 10, 2016 · 7:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 29, 2016 | A | 414 | $51.264 | A | 91,894 | D | |
| Common Stock | May 6, 2016 | F | 1,696 | $80.80 | D | 90,198 | D | |
| Common StockF2 | May 9, 2016 | S | 10,000 | $84.5532 | D | 80,198 | D | |
| Common StockF3 | May 10, 2016 | S | 4,658 | $86.3202 | D | 75,540 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person is reporting the purchase of shares of the issuer's Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2015, to April 30, 2016.
- F2The price in column 4 is the weighted average. The price actually ranged from $84.50 to $84.72. The reporting person shall provide to the issuer, and security holder of the issuer, or the SEC staff upon request, information regarding the number of shares sold at each price within the range.
- F3The price in column 4 is the weighted average. The price actually ranged from $86.3140 to $86.3210. The reporting person shall provide to the issuer, and security holder of the issuer, or the SEC staff upon request, information regarding the number of shares sold at each price within the range.